Insider trading

Period: 120 months Stock: TECH + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

123 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

123 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

123 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

123 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
123 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
123 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

123 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
8 May 2026
Herr Amy E. Director · indirect
Sold at will
$320.39K 6,636 at 48.28
97.1%
Sold half or more
17 Feb 2026
Herr Amy E. Director · indirect
Sold at will
$116.79K 1,976 at 59.11
90.8%
Sold half or more
25 Aug 2025
Nusse Roeland Director
Sold at will
$960.39K 17,040 at 56.36
27.7%
Not planned
25 Aug 2025
Sold at will
$957.82K 17,040 at 56.21
27.5%
Not planned
9 Jun 2025
Herr Amy E. Director · indirect
Sold at will
$63.70K 1,280 at 49.77
39.3%
Not planned
14 Feb 2025
Herr Amy E. Director · indirect
Sold at will
$122.69K 1,860 at 65.96
48.5%
Not planned
27 Jan 2025
Kelderman Kim Chief Executive Officer
Sold at will 2×
$1.04M 13,392 at 77.29
25.6%
Not planned
8 Aug 2024
Sold at will
$1.15M 16,000 at 72.10
26.9%
Not planned
14 May 2024
HIGGINS JOHN L Director
Sold at will
$335.38K 4,000 at 83.84
9.9%
Not planned
7 Mar 2024
Nusse Roeland Director
Sold at will
$800.63K 10,400 at 76.98
19.4%
Not planned
30 Aug 2023
Nusse Roeland Director
Sold at will
$717.96K 8,939 at 80.32
14.7%
Not planned
21 Jul 2023
Kummeth Charles R. Chief Executive Officer
Sold on a plan
$7.07M 80,000 at 88.36
6.0%
Planned (10b5-1)
7 Jun 2023
Kummeth Charles R. Chief Executive Officer
Sold at will
$26.73K 322 at 83.00
0.0%
Not planned
8 Dec 2022
Furlow Brenda S. SVP - GENERAL COUNSEL
Sold, plan not stated
$611.81K 7,450 at 82.12
22.2%
7 Dec 2022
Furlow Brenda S. SVP - GENERAL COUNSEL
Sold, plan not stated
$65.61K 800 at 82.01
3.0%
11 Aug 2022
HIGGINS JOHN L Director
Sold, plan not stated 2×
$197.32K 512 at 385.40
8.5%
10 Aug 2022
HIGGINS JOHN L Director
Sold, plan not stated 3×
$751.19K 1,992 at 377.11
24.9%
8 Jun 2022
HIGGINS JOHN L Director
Sold, plan not stated
$219.65K 600 at 366.09
11.5%
7 Jun 2022
Kummeth Charles R. CHIEF EXECUTIVE OFFICER
Sold, plan not stated
$1.86M 5,104 at 365.00
2.5%
7 Jun 2022
HIGGINS JOHN L Director
Sold, plan not stated
$364.31K 1,000 at 364.31
17.8%
10 May 2022
Bought
$105.77K 300 at 352.55
3.1%
First buy on file
19 Nov 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated 2×
$252.69K 500 at 505.38
100%
Sold half or more
12 Nov 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 10×
$13.69M 27,159 at 504.00
95.4%
Sold half or more
2 Nov 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$105.02K 200 at 525.10
1.8%
1 Nov 2021
Hippel James Chief Financial Officer
Sold, plan not stated 4×
$4.64M 8,822 at 526.52
45.1%
29 Oct 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$347.70K 662 at 525.23
5.8%
28 Oct 2021
Hippel James Chief Financial Officer
Sold, plan not stated
$52.52K 100 at 525.18
0.9%
22 Sep 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$434.87K 822 at 529.04
100%
Sold half or more
7 Sep 2021
STEER RANDOLPH C Director
Sold, plan not stated 3×
$4.08M 8,000 at 509.98
61.0%
Sold half or more
2 Sep 2021
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$5.07M 10,000 at 507.22
48.0%
2 Sep 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$3.50M 6,871 at 509.94
47.4%
31 Aug 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$2.53M 5,000 at 505.66
39.6%
31 Aug 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated
$773.73K 1,538 at 503.07
53.9%
Sold half or more
23 Aug 2021
Sold, plan not stated 6×
$1.94M 4,000 at 485.55
29.4%
23 Aug 2021
Nusse Roeland Director
Sold, plan not stated
$1.93M 4,000 at 481.52
37.2%
19 Aug 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 3×
$1.68M 3,538 at 473.95
31.7%
9 Aug 2021
Hippel James Chief Financial Officer
Sold, plan not stated 8×
$4.79M 10,000 at 478.90
48.0%
12 Jul 2021
Hippel James Chief Financial Officer
Sold, plan not stated 13×
$4.57M 10,000 at 456.67
52.3%
Sold half or more
18 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 2×
$1.31M 2,909 at 449.23
1.8%
17 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 4×
$4.31M 9,589 at 449.81
5.7%
14 Jun 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated 2×
$3.36M 7,481 at 449.15
4.3%
9 Jun 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$351.16K 811 at 433.00
100%
Sold half or more
7 Jun 2021
Hippel James Chief Financial Officer
Sold, plan not stated 6×
$4.19M 9,942 at 421.93
52.1%
Sold half or more
25 May 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$358.28K 845 at 424.00
51.0%
Sold half or more
12 Feb 2021
Hippel James Chief Financial Officer
Sold, plan not stated 2×
$4.00M 10,000 at 400.39
52.3%
Sold half or more
12 Feb 2021
Furlow Brenda S. SVP - General Counsel
Sold, plan not stated 2×
$3.99M 10,000 at 398.64
62.0%
Sold half or more
8 Feb 2021
Nusse Roeland Director
Sold, plan not stated
$2.31M 6,000 at 385.08
47.0%
5 Feb 2021
Eansor Norman David President-Protein Sciences
Sold, plan not stated 7×
$12.54M 32,933 at 380.68
96.2%
Sold half or more
5 Feb 2021
Kelderman Kim Pres. Diagnostics & Genom
Sold, plan not stated
$319.69K 823 at 388.45
49.3%
15 Jan 2021
Kummeth Charles R. Chief Executive Officer
Sold, plan not stated
$6.88M 20,000 at 344.00
12.0%
Showing 1–50 of 123. Page 1 of 3 Older →